2-Dimethylamino-N-(3-{4-[3-methyl-4-(pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide | 383430-82-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Dimethylamino-N-(3-{4-[3-methyl-4-(pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide
• 英文别名: 2-(dimethylamino)-N-[3-[4-(3-methyl-4-pyridin-3-yloxyanilino)quinazolin-6-yl]prop-2-ynyl]acetamide
• CAS: 383430-82-8
• 化学式: C₂₇H₂₆N₆O₂
• 分子量: 466.542
• InChiKey: AFNJRWJHTHPHFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  92.3
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-Dimethylamino-N-(3-{4-[3-methyl-4-(pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 0.05h， 生成 2-dimethylamino-N-(3-{4-[3-methyl-4-(pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide hydrochloride
  参考文献：
  名称：

  WO2006/129163

  摘要：

  公开号：
• 作为产物：
  描述：

  2-Chloro-N-(3-{4-[3-methyl-4-(pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide 、 二甲胺 以 四氢呋喃 、 甲醇 为溶剂， 反应 1.0h， 以99%的产率得到2-Dimethylamino-N-(3-{4-[3-methyl-4-(pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide
  参考文献：
  名称：

  Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer

  摘要：

  本发明涉及一种在哺乳动物中使用erbB2配体和抗体的组合治疗癌症的方法。更具体地，本发明涉及通过联合给予erbB2配体和erbB抗体来治疗癌症的方法。本发明还涉及一种在哺乳动物，特别是人类中治疗异常细胞生长的有用工具包。

  公开号：

  US20050101618A1

文献信息

• Combinations of signal transduction inhibitors
  申请人：Eck Louis Stephen

  公开号：US20050222163A1

  公开（公告）日：2005-10-06

  The present invention relates to methods for treating cancer comprising utilizing a combination of signal transduction inhibitors. More specifically, the present invention relates to combinations of so called cell cycle inhibitors with mitogen stimulated kinase signal transduction inhibitors, more specifically combinations of CDK inhibitors with mitogen stimulated kinase signal transduction inhibitors, more preferably MEK inhibitors. Other embodiments of the invention relate to additional combinations of the aforesaid combinations with standard anti-cancer agents such as cytotoxic agents, palliatives and antiangiogenics. Most specifically this invention relates to combinations of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one including salt forms, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor, in combination with one or more MEK inhibitors, most preferably N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide. The aforementioned combinations are useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.

  本发明涉及治疗癌症的方法，包括利用信号转导抑制剂的组合。更具体地，本发明涉及所谓的细胞周期抑制剂与促有丝分裂原刺激激酶信号转导抑制剂的组合，更具体地说是CDK抑制剂与促有丝分裂原刺激激酶信号转导抑制剂的组合，更优选地是MEK抑制剂的组合。本发明的其他实施例涉及上述组合与标准抗癌药物（如细胞毒性药物、缓解剂和抗血管生成药物）的额外组合。最具体地，本发明涉及包括盐形式的6-乙酰基-8-环戊基-5-甲基-2-(5-哌嗪-1-基-吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮，这是一种选择性细胞周期蛋白依赖性激酶4（CDK4）抑制剂，与一种或多种MEK抑制剂结合，最好是N-[(R)-2,3-二羟基-丙氧基]-3,4-二氟-2-(2-氟-4-碘苯氨基)-苯甲酰胺。前述组合对于治疗炎症和细胞增殖性疾病如癌症和再狭窄症是有用的。
• Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer
  申请人：Connell D. Richard

  公开号：US20050101618A1

  公开（公告）日：2005-05-12

  This invention relates to a method of treatment of cancer with a combination of an erbB2 ligand and an antibody, in mammals. More particularly, this invention relates to a method of treating cancer by administering an erbB2 ligand in combination with an erbB antibody. This invention also relates to a kit useful in the treatment of abnormal cell growth in mammals, especially humans.

  本发明涉及一种在哺乳动物中使用erbB2配体和抗体的组合治疗癌症的方法。更具体地，本发明涉及通过联合给予erbB2配体和erbB抗体来治疗癌症的方法。本发明还涉及一种在哺乳动物，特别是人类中治疗异常细胞生长的有用工具包。
• Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
  申请人：Pfizer Inc.

  公开号：US20030144506A1

  公开（公告）日：2003-07-31

  The invention relates to processes for preparing compounds of the formula 1 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R 1 , R 3 , R 4 , R 5 , R 11 , m and p are as defined herein. The compounds of formula 1 are useful in treating abnormal cell growth in mammals by administering pharmaceutical compositions.

  本发明涉及制备式11化合物的过程，以及其药学上可接受的盐、前药和溶剂化物，其中R1、R3、R4、R5、R11、m和p的定义如本文所述。式1化合物在哺乳动物中通过给予药物组成物来治疗异常细胞生长。
• Substituted bicyclic derivatives for the treatment of abnormal cell growth
  申请人：——

  公开号：US20020169165A1

  公开（公告）日：2002-11-14

  The invention relates to compounds of the formula 1 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R 1 , R 3 , R 4 , R 5 , R 11 , m and p are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  该发明涉及公式11的化合物，以及其药学上可接受的盐、前药和溶剂化物，其中R1、R3、R4、R5、R11、m和p如本文所定义。该发明还涉及通过给予公式1的化合物治疗哺乳动物的异常细胞增长的方法，并且涉及用含有公式1的化合物的制药组合物治疗这种疾病的方法。该发明还涉及制备公式1的化合物的方法。
• [EN] PROCESSES FOR THE PREPARATION OF SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH<br/>[FR] PROCEDES DE PREPARATION DE DERIVES BICYCLIQUES SUBSTITUES UTILISE POUR TRAITER LA CROISSANCE CELLULAIRE ANORMALE
  申请人：PFIZER PROD INC

  公开号：WO2003045939A1

  公开（公告）日：2003-06-05

  The invention relates to processes for preparing compounds of formula (1) and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R?1, R3, R4, R5, R11¿, m and p are as defined herein. The compounds of formula (1) are useful in treating abnormal cell growth in mammals by administering pharmaceutical compositions.

  本发明涉及制备式（1）化合物的过程，以及其药学上可接受的盐、前药和溶剂化物，其中R?1、R3、R4、R5、R11、m和p如本文所定义。式（1）化合物可通过给哺乳动物施用药物组成物来治疗异常细胞生长。